Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Abbott Healthcare Products Limited
Solvay Healthcare, Mansbridge Road, West End, Southampton, SO18 3JD
Telephone: +44 (0)2380 467 000
Fax: +44 (0)2380 465 350
Medical Information e-mail: medinfo.shl@abbott.com
Customer Care direct line: +44 (0)1753 650 099
Medical Information Fax: +44 (0)2380 465 350

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 15/11/2011
SPC Klaricid Paediatric Suspension 125mg/5ml

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 15/11/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic Properties
Updated on 17/02/2011 and displayed until 15/11/2011
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic indications
Updated on 01/02/2010 and displayed until 17/02/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 08/01/2010 and displayed until 01/02/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 date of revision of the text
Updated on 27/10/2009 and displayed until 08/01/2010
Reasons for adding or updating:
  • Change to section 6.1 - List of Excipients
Updated on 19/09/2006 and displayed until 27/10/2009
Reasons for adding or updating:
  • Change to section 4.3 - Contra-indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 11/10/2005 and displayed until 19/09/2006
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 (date of (partial) revision of the text
Updated on 23/08/2001 and displayed until 11/10/2005
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC
Updated on 06/09/1999 and displayed until 23/08/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  clarithromycin